New hope for controlling rare childhood epilepsy
NCT ID NCT04873869
Summary
This study tested whether adding a new drug called NBI-921352 to a patient's current seizure medications could help reduce seizure frequency in children and young adults with a rare genetic epilepsy called SCN8A-DEE. It was a Phase 2 trial that compared the drug to a placebo (inactive substance) in a small group of participants. The main goal was to see if the drug was safe and effective at lowering the number of countable motor seizures over a 16-week treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
UCSF Medical Center
San Francisco, California, 94158, United States
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.